# Selinexor and Backbone Treatments of Multiple Myeloma Patients

Source: https://onco.cc/trials/nct02343042/  
OnCo record `nct02343042` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Selinexor, Dexamethasone, Lenalidomide in multiple myeloma, run by Karyopharm Therapeutics Inc, now recruiting.

## Summary

Selinexor and Backbone Treatments of Multiple Myeloma Patients is a phase 1/2 interventional study registered as NCT02343042 by Karyopharm Therapeutics Inc, with 300 participants planned, started 2015-10 and due to reach its primary completion in 2027-04. Interventions recorded: Selinexor, Dexamethasone, Lenalidomide, Pomalidomide, Bortezomib. Conditions listed: Multiple Myeloma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT02343042
- Phase: 1/2
- Setting: A Phase 1b/2 Study of Selinexor (KPT-330) in Combination With Backbone Treatments for Relapsed/Refractory Multiple Myeloma and Newly Diagnosed Multiple Myeloma
- Sponsor: Karyopharm Therapeutics Inc
- Enrolled: 300

## Sources

- ClinicalTrials.gov NCT02343042: https://clinicaltrials.gov/study/NCT02343042

## Connected records

- cancers: [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/)
- drugs: [Bortezomib](https://onco.cc/drugs/bortezomib/), [Daratumumab](https://onco.cc/drugs/daratumumab/), [Dexamethasone](https://onco.cc/drugs/dexamethasone/), [Lenalidomide](https://onco.cc/drugs/lenalidomide/), [Pomalidomide](https://onco.cc/drugs/pomalidomide/), [Selinexor](https://onco.cc/drugs/selinexor/)
- companies: [Karyopharm Therapeutics](https://onco.cc/companies/karyopharm/)

---
JSON: https://onco.cc/api/v1/entities/nct02343042.json